Indivior Pharmaceuticals, Inc. Operating Cash Flow
Indivior Pharmaceuticals, Inc. (SUPN) reported Operating Cash Flow of $220.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-03
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was $229.00M, a 44.94% increase year-over-year.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$9.00M, a 112.00% decline year-over-year.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$221.00M.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$39.00M, a 2050.00% decline year-over-year.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2025 was -$27.00M, a 175.00% decline from fiscal 2024.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2024 was $36.00M.
- Indivior Pharmaceuticals, Inc. net cash provided by (used in) operating activities for fiscal 2023 was -$300.00M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $229.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $220.00M 10-Q · filed 2026-08-03 | -$1.00M derived: sum of 3 quarters · filed 2026-08-03 | -$40.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2026-03-31 | -$9.00M 10-Q · filed 2026-04-30 | -$230.00M derived: sum of 2 quarters · filed 2026-04-30 | -$269.00M derived: sum of 3 quarters · filed 2026-04-30 | -$111.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-12-31 | -$221.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$260.00M derived: sum of 2 quarters · filed 2026-02-26 | -$102.00M derived: sum of 3 quarters · filed 2026-08-03 | -$27.00M 10-K · filed 2026-02-26 |
| 2025-09-30 | -$39.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $119.00M derived: sum of 2 quarters · filed 2026-08-03 | $194.00M 10-Q · filed 2025-10-30 | $177.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-06-30 | $158.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | $233.00M 10-Q · filed 2026-08-03 | $216.00M derived: sum of 3 quarters · filed 2026-08-03 | $218.00M derived: sum of 4 quarters · filed 2026-08-03 |
| 2025-03-31 | $75.00M 10-Q · filed 2026-04-30 | $58.00M derived: sum of 2 quarters · filed 2026-04-30 | $60.00M derived: sum of 3 quarters · filed 2026-04-30 | $148.00M derived: sum of 4 quarters · filed 2026-04-30 |
| 2024-12-31 | -$17.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | -$15.00M derived: sum of 2 quarters · filed 2026-02-26 | $73.00M derived: sum of 3 quarters · filed 2026-02-26 | $36.00M 10-K · filed 2026-02-26 |
| 2024-09-30 | $2.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-10-30 | $90.00M derived: sum of 2 quarters · filed 2025-10-30 | $53.00M 10-Q · filed 2025-10-30 | |
| 2024-06-30 | $88.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-07-31 | $51.00M 10-Q · filed 2025-07-31 | ||
| 2024-03-31 | -$37.00M 10-Q · filed 2025-05-01 | |||
| 2023-12-31 | -$300.00M 10-K · filed 2026-02-26 | |||
| 2022-12-31 | -$4.00M 10-Q · filed 2025-10-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| MBX Biosciences, Inc. (MBX) | United States | $2.664B | -25.36 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |